Parabilis Medicines
About Parabilis Medicines
Products & Services
Specialties
Funding History
Debug: View Raw Funding Data
| # | Type | Amount Fields | Date Fields | Investors |
|---|---|---|---|---|
| 1 |
RT: IPO T: - FT: IPO |
A: 845500000 MR: - FA: $845.5 million FAN: 845500000 |
D: 2026-06-11 FD: 2026-06-11 |
2 investors |
| 2 |
RT: IPO T: - FT: IPO |
A: 670000000 MR: - FA: 670000000 FAN: 670000000 |
D: 2026-06-09 FD: 2026-06-09 |
6 investors |
| 3 |
RT: Series F T: - FT: Series F |
A: 305000000 MR: - FA: $305 million FAN: 305000000 |
D: 2026-01-08 FD: 2026-01-08 |
23 investors |
Growth Metrics
Team & Leadership
Mathai Mammen
Chairman, CEO and President
Fawzi Benzaghou
Chief Medical Officer
Markus Haeberlein
Executive Vice President, Discovery Science
Helen Ho
Chief Business and Strategy Officer
Jonathan Hurov
Executive Vice President, Discovery Biology
Teresa Jurgensen
Executive Vice President, General Counsel
Recent News
Parabilis Medicines Announces New Product Launch
2 days agoCompany unveils innovative solution to transform the industry, expanding market reach and capabilities...
Read more →Leadership Team Expands with Industry Veteran
1 week agoNew executive brings 20+ years of experience to accelerate growth and strategic initiatives...
Read more →Company Recognized as Industry Leader
2 weeks agoReceives prestigious award for innovation and customer satisfaction in competitive market...
Read more →Key Competitors
Competitor Alpha
Series B · $50M raised
Competitor Beta
Series C · $120M raised
Competitor Gamma
Series A · $25M raised
Competitor Delta
Seed · $10M raised
Company Details
- Website
- parabilismed.com
- Industries
- Biotechnology/Pharmaceuticals
- Company Size
- ~700 employees (est.)
- Locations
-
Cambridge, Massachusetts, USA
Cambridge, MA, USA
Cambridge, Massachusetts
Technology Stack
Discover the backend, frontend, and infrastructure technologies powering this company's products.
Upgrade to Pro